Fate Therapeutics will present at the Piper Sandler Healthcare Conference on December 2, 2025, discussing its iPSC-derived therapies.
Quiver AI Summary
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases, announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York City. Company management will engage in a fireside chat at 9:00 AM ET and participate in a cell therapy panel discussion at 12:00 PM ET. A live webcast of these presentations will be available on the company's website, along with an archived version post-event. Fate Therapeutics aims to lead in the creation of advanced iPSC-derived cell therapies and has developed a pipeline of products including natural killer (NK) cells and T-cells designed for effective therapeutic applications.
Potential Positives
- Fate Therapeutics will present at a prominent industry conference, the Piper Sandler 37th Annual Healthcare Conference, which can enhance visibility and credibility among investors and industry peers.
- The participation in a fireside chat and a panel discussion indicates active engagement with the investment community, showcasing the company’s leadership and innovative product pipeline.
- The company's focus on first-in-class, iPSC-derived cellular immunotherapies underscores its commitment to advancing cutting-edge treatments for cancer and autoimmune diseases, potentially positioning it as a leader in this therapeutic area.
Potential Negatives
- None
FAQ
What is Fate Therapeutics known for?
Fate Therapeutics is known for its first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases.
When will Fate Therapeutics present at the Piper Sandler conference?
Fate Therapeutics will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025.
Where is Fate Therapeutics headquartered?
Fate Therapeutics is headquartered in San Diego, California.
How can I access the live webcast of the presentations?
The live webcast of the presentations can be accessed in the “Events & Presentations” section of the Company’s website.
What types of products are included in Fate Therapeutics' pipeline?
The pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates designed for multiple therapeutic mechanisms.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FATE Insider Trading Activity
$FATE insiders have traded $FATE stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $FATE stock by insiders over the last 6 months:
- BAHRAM VALAMEHR (President and CEO) sold 14,466 shares for an estimated $15,396
- CINDY TAHL (See Remarks) sold 9,037 shares for an estimated $9,572
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FATE Hedge Fund Activity
We have seen 65 institutional investors add shares of $FATE stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WILSHIRE ADVISORS LLC added 8,486,822 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,693,395
- CITADEL ADVISORS LLC removed 3,719,322 shares (-81.9%) from their portfolio in Q3 2025, for an estimated $4,686,345
- BAKER BROS. ADVISORS LP removed 2,485,018 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,131,122
- CITIGROUP INC removed 1,893,164 shares (-99.4%) from their portfolio in Q3 2025, for an estimated $2,385,386
- ORBIMED ADVISORS LLC removed 1,680,580 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,882,249
- MORGAN STANLEY removed 1,503,631 shares (-61.8%) from their portfolio in Q3 2025, for an estimated $1,894,575
- RENAISSANCE TECHNOLOGIES LLC added 1,048,052 shares (+488.7%) to their portfolio in Q3 2025, for an estimated $1,320,545
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FATE Analyst Ratings
Wall Street analysts have issued reports on $FATE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/31/2025
- Wedbush issued a "Outperform" rating on 10/27/2025
To track analyst ratings and price targets for $FATE, check out Quiver Quantitative's $FATE forecast page.
$FATE Price Targets
Multiple analysts have issued price targets for $FATE recently. We have seen 3 analysts offer price targets for $FATE in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Robert Burns from HC Wainwright & Co. set a target price of $5.0 on 10/31/2025
- David Nierengarten from Wedbush set a target price of $7.0 on 10/27/2025
- Yanan Zhu from Wells Fargo set a target price of $2.5 on 08/13/2025
Full Release
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the Piper Sandler 37 th Annual Healthcare Conference on Tuesday, December 2, 2025 in New York, New York. Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET.
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com . The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit
www.fatetherapeutics.com
.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
[email protected]
